ACS Global

What ACS Global does

ACS Global, operating under the consumer-facing brand American CryoStem, is a publicly traded company (OTC Pink: AMCY) founded in 1987 and headquartered in Eatontown, New Jersey. The company provides autologous stem cell preservation services to individuals, enabling private collection, processing, and long-term cryogenic storage of biological specimens for potential future use in cell therapy and regenerative medicine applications. Its core offering combines a laboratory-based cell processing capability (evidenced by a Chief Scientist and a VP Senior Laboratory Supervisor) with consumer-facing logistics for specimen intake and storage.

The company's primary revenue mechanic is consumer-pay, recurring storage fees tied to long-duration preservation contracts; the underlying technology centers on cryogenic tissue banking infrastructure rather than a software or platform product. The firm is small (11-50 employees) and has historically relied on modest equity financings, with two disclosed rounds in 2011 totaling approximately $3.16M and a 2015 acquisition of BioLife Cell Bank that broadened its preservation footprint. The corporate website (americancryostem.com) currently renders as an exposed directory listing with file extensions indicating compromised or poorly maintained infrastructure, which is a material operational concern for any consumer-facing health services business. The management team includes a Chairman/CEO, COO, Chief Scientist, and laboratory leadership, with two physicians on the board providing clinical oversight.

Name

ACS Global

Website

https://americancryostem.com

Company type

Private

Founded year

1987

Headcount range

11–50 employees

Short description

ACS Global (American CryoStem, OTC: AMCY) is a publicly traded, New Jersey-based autologous stem cell preservation company that collects, processes, and cryogenically stores individuals' biological specimens for potential future use in cell therapy and regenerative medicine.

Ownership category

akta.pro rank

Product category

Stem Cell Banking Services

NAICS

Blood and Organ Banks (621991)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Stem cell banking
• Cell preservation
• Tissue storage
• Regenerative medicine
• Cryopreservation services

Headquarters

HQ city

Eatontown

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Core offering

ACS Global offers private adult stem cell banking services, enabling individuals to collect, process, and cryogenically store their own stem cells for potential future use in cell therapy and regenerative medicine. The company operates as a for-profit, publicly traded stem cell preservation provider serving consumer clients seeking autologous cellular preservation.

Differentiator

Problem solved

Functional benefit

Products and services

• Private Adult Stem Cell Banking Service

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights2 records

Direct peers

• Cells4Life: UK private cord blood and tissue bank offering multiple processing and storage options; directly comparable to ACS Global's elective family banking service.
• Cord Blood Registry (CBR): Largest U.S. private cord blood bank, offering elective family banking of cord blood stem cells — directly competes for the same parent-consumer segment as ACS Global.
• ViaCord: PerkinElmer-owned cord blood banking service focused on private family storage of newborn stem cells, overlapping ACS Global's elective autologous preservation offering.
• StemCyte: Hybrid public/private cord blood bank offering both family and public-donor storage, with therapeutic processing capabilities comparable to ACS Global's biobanking model.
• Future Health Biobank: UK-based private stem cell and tissue bank providing family cord blood and tissue storage with international reach — a direct peer in elective autologous biobanking.
• Esperite NV (The Cell Factory / CryoSave): European-headquartered family stem cell banking group offering cord blood and tissue storage services directly comparable to ACS Global's autologous preservation business.
• Cryo-Cell International: U.S.-based public cord blood and menstrual blood stem cell bank offering private family banking services directly comparable to ACS Global's autologous preservation model.
• Smart Cells International: UK private stem cell bank specializing in cord blood and tissue storage with international shipping — competes in the same elective family banking category as ACS Global.

Emerging players

• Celularity Inc. Clinical-stage cell therapy company leveraging placental and postpartum-derived cells; overlaps as a downstream consumer of preserved cellular material relevant to ACS Global's future-use thesis.

Regional players

• Hemacord (FDA-licensed HPC-C service): FDA-licensed public cord blood banking operator offering regulated hematopoietic progenitor cell products; comparable as an adjacent cell banking/tissue storage operator in the U.S.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/cryostem
• Facebookfacebook.com/AmericanCryoStem
• LinkedInlinkedin.com/company/american-cryostem-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACS Global